{"id":441440,"date":"2021-02-23T03:24:38","date_gmt":"2021-02-23T08:24:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=441440"},"modified":"2021-02-23T03:24:38","modified_gmt":"2021-02-23T08:24:38","slug":"bioinvent-international-financial-statement-january-1-december-31-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/","title":{"rendered":"BioInvent International Financial Statement January 1 &#8211; December 31, 2020"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Promising early interim efficacy data on our lead drug candidate<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">LUND, Sweden<\/span>, <span class=\"xn-chron\">Feb. 23, 2021<\/span> \/PRNewswire\/ &#8212; <i>&#8220;BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy data from the ongoing Phase I\/IIa trial of our lead drug candidate BI-1206.The company also closed a successful <span class=\"xn-money\">SEK 962 million<\/span> financing round, expanding our institutional shareholder base. Furthermore, we announced the expansion of our clinical pipeline to include two further drug candidates for the treatment of solid tumors.&#8221; &#8211;\u00a0Martin Welschof, CEO BioInvent<\/i><\/p>\n<p>\u00a0<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Financial information <\/p>\n<p class=\"prnews_p\"><span class=\"prnews_span\"><i><b>Fourth quarter 2020<\/b><\/i><\/span><\/p>\n<p><\/span><\/p>\n<p class=\"prnews_p\" \/>\n<p class=\"prnml20\">\n                  <span class=\"prnews_span\">&#8211; Net sales SEK 98.7 (25.4) million.<\/span>\n                <\/p>\n<p class=\"prnml20\">\n                  <span class=\"prnews_span\">&#8211; Profit\/loss after tax SEK 28.5 \u00a0(-40.9) million.<\/span>\n                <\/p>\n<p class=\"prnml20\">\n                  <span class=\"prnews_span\">&#8211; Profit\/loss after tax per share before and after dilution SEK 0.74\u00a0 (-2.04).<\/span>\n                <\/p>\n<p class=\"prnml20\">\n                  <span class=\"prnews_span\">&#8211; Cash flow from operating activities and investment activities SEK 27.6\u00a0 (-28.5) million.<\/span>\n                <\/p>\n<p class=\"prnews_p\" \/>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i><br \/>\n                    <b>January &#8211; December 2020<\/b><br \/>\n                  <\/i><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnml20\">\n                <span class=\"prnews_span\">&#8211; Net sales SEK 147.4 (93.7) million.<\/span>\n              <\/p>\n<p class=\"prnml20\">\n                <span class=\"prnews_span\">&#8211; Loss after tax SEK -76.3 \u00a0(-138.6) million.<\/span>\n              <\/p>\n<p class=\"prnml20\">\n                <span class=\"prnews_span\">&#8211; Loss after tax per share before and after dilution SEK\u00a0 -2.66 (-7.64).<\/span>\n              <\/p>\n<p class=\"prnml20\">\n                <span class=\"prnews_span\">&#8211; Cash flow from operating activities and \u00a0investment activities SEK -69.3 \u00a0(-129.3) million.\u00a0Liquid funds as of December 31, 2020: SEK 729.3 (154.0) million.<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Financial information first quarter 2020<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnml20\">\n                <span class=\"prnews_span\">&#8211; Net sales SEK 16.7 (17.4) million.<\/span>\n              <\/p>\n<p class=\"prnml20\">\n                <span class=\"prnews_span\">&#8211; Loss after tax SEK -32.6 (-27.8) million.<\/span>\n              <\/p>\n<p class=\"prnml20\">\n                <span class=\"prnews_span\">&#8211; Loss after tax per share before and after dilution SEK -0.07 \u00a0(-0.08).<\/span>\n              <\/p>\n<p class=\"prnml20\">\n                <span class=\"prnews_span\">&#8211; Cash flow from operating activities and investment activities SEK -35.4 \u00a0(-40.5) million. Liquid funds as of March 31, 2020: SEK 117.1 (28.5) million.<\/span>\n              <\/p>\n<\/td>\n<td class=\"prnsbt1 prnsbr1 prnvab prnsbb1 prntar prnpl6 prnsbl1 prnpr6\">\n              \n            <\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<p>\n        <b>Events in the fourth quarter<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>BI-1206 was out-licensed to CASI Pharmaceuticals for the <span class=\"xn-location\">Greater China<\/span> region. The collaboration accelerates and expands BioInvent&#8217;s global development plans for BI-1206. BioInvent received <span class=\"xn-money\">$12 million<\/span> upfront in combination of cash and equity investment and is eligible to receive up to <span class=\"xn-money\">$83 million<\/span> in milestone payments, plus tiered royalties. The equity investment was approved at an EGM held on <span class=\"xn-chron\">November 27, 2020<\/span>. (R) <\/li>\n<li>BioInvent received a <span class=\"xn-money\">$3 million<\/span> milestone payment related to selection of antibodies under its collaboration with Pfizer. (R) <\/li>\n<li>Approval of a CTA was received in <span class=\"xn-location\">Denmark<\/span> for the Phase I\/IIa study of BI-1808, as monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). <\/li>\n<li>BioInvent and Transgene received CTA approval for Phase l\/lla trial of oncolytic virus BT-001 in solid tumors. <\/li>\n<li>New preclinical data was presented on BI-1808 and BT-001 at the SITC 35th Anniversary Annual Meeting. New promising clinical and preclinical data on BI-1206 was also presented at the ASH Annual Meeting. <\/li>\n<li>BioInvent received a \u20ac2 million milestone payment under its collaboration with Daiichi Sankyo related to the initiation of a global Phase I clinical trial with a GARP directed antibody. (R) <\/li>\n<li>BioInvent and Cantargia signed a manufacturing agreement, which may generate revenue for BioInvent of up to <span class=\"xn-money\">SEK 30 million<\/span>. <\/li>\n<li>BioInvent announced the appointment of <span class=\"xn-person\">Cecilia Hofvander<\/span> as Senior Director Investor Relations, a new position at BioInvent starting <span class=\"xn-chron\">mid-February 2021<\/span>. <\/li>\n<li>The EGM held on <span class=\"xn-chron\">November 27, 2020<\/span> approved the proposal on a reverse share split 1:25, a reduction of the share capital to adjust the share capital to the Company&#8217;s operations, and an updated authorization for the Board to decide on a new issue of shares comprising 4,375,121 shares (after the reverse share split). (R)<\/li>\n<\/ul>\n<p>\n        <b>Events after the reporting period<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>In <span class=\"xn-chron\">January 2021<\/span>, BioInvent announced that Phase I\/IIa data suggest that BI-1206 restores activity of rituximab in relapsed non-Hodgkin&#8217;s lymphoma patients. Responses in 6 out of 9 patients evaluated provide exciting evidence that BI-1206 has the potential to restore activity of rituximab in non-Hodgkin&#8217;s lymphoma patients who have relapsed after treatment with rituximab. Long-lasting complete responses observed in two patients beyond 12 months. (R) <\/li>\n<li>On <span class=\"xn-chron\">February 23, 2021<\/span>, BioInvent successfully completed a directed share issue of approximately <span class=\"xn-money\">SEK 962 million<\/span> before transaction costs. Investors in the directed share issue are a range of international and Swedish investors, including Redmile Group, LLC., Invus, HBM Healthcare Investments, The Fourth National Swedish Pension Fund, Swedbank Robur Fonder and Van Herk Investments. 2,834,399 new shares were issued based on the authorization granted by the EGM on <span class=\"xn-chron\">November 27, 2020<\/span>, and 16,260,601 new shares were issued subject to the approval of an EGM to be held on <span class=\"xn-chron\">23 March 2021<\/span>. (R) <\/li>\n<li>In <span class=\"xn-chron\">January 2021<\/span>, BioInvent announced that it had restructured a clinical development agreement with Cancer Research UK (CRUK) for BI-1206. In exchange for a one-time payment of \u00a32.5 million, the revised deal simplifies and reduces Bioinvent&#8217;s obligations to CRUK. (R) <\/li>\n<li>BioInvent announced in <span class=\"xn-chron\">January 2021<\/span>, enrollment of the first patient in a Phase I\/IIa study of BI-1808. <\/li>\n<li>o\u00a0 In <span class=\"xn-chron\">January 2021<\/span>, BioInvent announced that An van Es Johansson should resign as a director of the board effective as of <span class=\"xn-chron\">15 February 2021<\/span>, due to personal reasons. (R)<\/li>\n<\/ul>\n<p>(R)=\u00a0Regulatory event<\/p>\n<p>\n        <b>Comments from the CEO<\/b>\n      <\/p>\n<p>BioInvent has started 2021 with significant positive momentum. Promising\u00a0interim efficacy data from the ongoing Phase I\/IIa trial of our lead drug candidate BI-1206 was followed by a successful financing round, adding another specialized institutional owner to the company. Furthermore, we announced the expansion of our clinical pipeline to include two further drug candidates.<\/p>\n<p>The data from the study of BI-1206, in combination with rituximab in patients with indolent relapsed or refractory B-cell non-Hodgkin&#8217;s lymphoma (NHL), are very encouraging. The responses in these severely ill patients\u00a0suggest that BI-1206 may restore the response to rituximab in patients who have few treatment alternatives. Furthermore, the duration of complete response in two patients are particularly impressive and indicate that BI-1206 has the potential to significantly improve the lives of NHL patients who have progressed after previous lines of treatment.<\/p>\n<p>We were proud to host a key opinion leader (KOL) event on these results with renowned lymphoma expert Professor <span class=\"xn-person\">Mats Jerkeman<\/span>, MD, of <span class=\"xn-location\">Lund<\/span> University. Based on these results, we will now move to identify the recommended dose for the Phase IIa part of the study. We also presented new data on BI-1206 at the ASH Annual Meeting in December and are excited to further evaluate its potential to bring much needed innovation to lymphoma patients.<\/p>\n<p>This progress is reinforced by our partnership with CASI Pharmaceuticals for the development and commercialization of BI-1206 in mainland <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">Taiwan<\/span>, <span class=\"xn-location\">Hong Kong<\/span> and <span class=\"xn-location\">Macau<\/span>. Under this agreement for both liquid and solid cancers, BioInvent received <span class=\"xn-money\">$12 million<\/span> upfront in combination of cash and equity investment and is eligible to receive up to <span class=\"xn-money\">$83 million<\/span> in development and commercial milestone payments plus tiered royalties in the high-single to mid-double-digit range on net sales. CASI is a proven leader in <span class=\"xn-location\">China<\/span> and their clinical development and regulatory expertise will be important in generating additional data on BI-1206.<\/p>\n<p>We have simplified and reduced our obligations to CRUK related to BI-1206 by restructuring our clinical development agreement with CRUK (Cancer Research UK) for BI-1206, in exchange for a one-time payment. This provides us with further flexibility to carry out development and partnering activities with BI-1206.<\/p>\n<p>Our innovative pipeline is expanding beyond BI-1206. We now have three products in clinical development, underlining the ability of our n-CoDeR<sup>\u00ae<\/sup>\/F.I.R.S.T\u2122 platforms to produce novel, differentiating drug candidates. <\/p>\n<p>In January, we enrolled the first patient in a Phase I\/IIa, first-in-human study of BI-1808, a first-in-class anti-TNFR2 antibody, as monotherapy and in combination with the anti-PD-1 therapy Keytruda<sup>\u00ae<\/sup> (pembrolizumab) for the treatment of solid tumors and CTCL. This is based on a solid preclinical data set for BI-1808, including the new data presented at the 35th Annual Meeting of SITC in November.<\/p>\n<p>We have now received CTA approval to start a Phase I\/IIa clinical trial of the novel oncolytic vaccinia virus BT-001 in solid tumors, through our collaboration with Transgene. BT-001 combines multiple mechanisms of action and has outstanding potential in a wide range of indications due to its combination of multiple anti-cancer properties. We also presented new data on BT-001 at SITC.<\/p>\n<p>On <span class=\"xn-chron\">February 23<\/span>, we further reinforced our financial position with a directed share issue that raised approximately <span class=\"xn-money\">SEK 962 million<\/span> before transaction costs. These proceeds intend to fund the continued transformation of BioInvent and expansion of our clinical programs. Assuming continued generation of positive data, we plan to in particular use the funds to prepare a pivotal clinical trial of BI-1206 for the treatment of NHL, with the aim of receiving an accelerated regulatory pathway. We also expect to expand the clinical programs of BI-1206 in combination with Keytruda<sup>\u00ae<\/sup> and BI-1808 as monotherapy and in combination with Keytruda<sup>\u00ae<\/sup>.<\/p>\n<p>Our partner Pfizer has selected antibodies, directed at a previously selected target, under our agreement covering developing antibodies from the F.I.R.S.T<sup>TM<\/sup> drug discovery platform targeting tumor-associated myeloid cells. This is an impressive example of the productivity of our platform and further strengthens our financial position by <span class=\"xn-money\">$3 million<\/span>. We may now move forward to develop other antibodies internally or with other partners.\u00a0 <\/p>\n<p>We also generated important revenue from a \u20ac2 million milestone payment under a collaboration with Daiichi Sankyo and we signed a new manufacturing agreement with Cantargia, under which BioInvent may generate revenue of up to <span class=\"xn-money\">SEK 30 million<\/span>.<\/p>\n<p>As previously communicated, BioInvent has taken all the necessary precautions with regards to managing the impact of Covid-19. Although we still observe viral spread throughout the community, which is of course terrible for all those affected and their families, we remain on track with our clinical trials and results. As the situation is still evolving, timelines may be impacted in geographic areas most severely affected. We will provide updates as necessary.<\/p>\n<p>The company has made significant progress in delivering on our strategy in 2020 and this has set us up for a number of important milestones as we progress our portfolio through clinical development. 2021 promises to be a very exciting year for BioInvent. <\/p>\n<p>Martin Welschof, CEO<\/p>\n<p>\n        <b>Read the complete report in the attached pdf.<\/b>\n      <\/p>\n<p>\n        <b>Contact:<\/b>\n      <\/p>\n<p>Any questions regarding this report will be answered by Martin Welschof, CEO, +46 (0)46 286 85 50, <a target=\"_blank\" href=\"mailto:martin.welschof@bioinvent.com\" rel=\"nofollow noopener noreferrer\">martin.welschof@bioinvent.com<\/a>. The report is also available at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3075632-1&amp;h=3937255092&amp;u=http%3A%2F%2Fwww.bioinvent.com%2F&amp;a=www.bioinvent.com\" rel=\"nofollow noopener noreferrer\">www.bioinvent.com<\/a>.<\/p>\n<p>BioInvent International AB (publ)<br \/>Co. reg. no. 556537-7263<br \/>Address: S\u00f6lvegatan 41, 223 70 Lund<br \/>Tel.: +46 (0)46 286 85 50<\/p>\n<p>\n        <b>Forward looking information<\/b>\n      <\/p>\n<p>This interim report contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual out-come may deviate significantly from the scenarios described in this interim report.<\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3075632-1&amp;h=285165694&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3075632-1&amp;h=2864874948&amp;u=https%3A%2F%2Fnews.cision.com%2Fbioinvent%2Fr%2Fbioinvent-international-financial-statement-january-1---december-31--2020%2Cc3293713&amp;a=https%3A%2F%2Fnews.cision.com%2Fbioinvent%2Fr%2Fbioinvent-international-financial-statement-january-1---december-31--2020%2Cc3293713\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/bioinvent\/r\/bioinvent-international-financial-statement-january-1&#8212;december-31&#8211;2020,c3293713<\/a>\n      <\/p>\n<p>The following files are available for download:<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnsbt1 prnsbr1 prnsbb1 prnsbl1\">\n<tr>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3075632-1&amp;h=3858458158&amp;u=https%3A%2F%2Fmb.cision.com%2FMain%2F583%2F3293713%2F1377403.pdf&amp;a=https%3A%2F%2Fmb.cision.com%2FMain%2F583%2F3293713%2F1377403.pdf\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">https:\/\/mb.cision.com\/Main\/583\/3293713\/1377403.pdf<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">BioInvent International Financial Statement January 1 &#8211; December 31, 2020<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO87845&amp;sd=2021-02-23\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/bioinvent-international-financial-statement-january-1---december-31-2020-301233133.html\">http:\/\/www.prnewswire.com\/news-releases\/bioinvent-international-financial-statement-january-1&#8212;december-31-2020-301233133.html<\/a><\/p>\n<p>SOURCE  BioInvent<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO87845&amp;Transmission_Id=202102230320PR_NEWS_USPR_____IO87845&amp;DateId=20210223\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Promising early interim efficacy data on our lead drug candidate PR Newswire LUND, Sweden, Feb. 23, 2021 \/PRNewswire\/ &#8212; &#8220;BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy data from the ongoing Phase I\/IIa trial of our lead drug candidate BI-1206.The company also closed a successful SEK 962 million financing round, expanding our institutional shareholder base. Furthermore, we announced the expansion of our clinical pipeline to include two further drug candidates for the treatment of solid tumors.&#8221; &#8211;\u00a0Martin Welschof, CEO BioInvent \u00a0 Financial information Fourth quarter 2020 &#8211; Net sales SEK 98.7 (25.4) million. &#8211; Profit\/loss after tax SEK 28.5 \u00a0(-40.9) million. &#8211; Profit\/loss after tax per share before and after dilution SEK 0.74\u00a0 (-2.04). &#8211; &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioInvent International Financial Statement January 1 &#8211; December 31, 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-441440","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioInvent International Financial Statement January 1 - December 31, 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioInvent International Financial Statement January 1 - December 31, 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Promising early interim efficacy data on our lead drug candidate PR Newswire LUND, Sweden, Feb. 23, 2021 \/PRNewswire\/ &#8212; &#8220;BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy data from the ongoing Phase I\/IIa trial of our lead drug candidate BI-1206.The company also closed a successful SEK 962 million financing round, expanding our institutional shareholder base. Furthermore, we announced the expansion of our clinical pipeline to include two further drug candidates for the treatment of solid tumors.&#8221; &#8211;\u00a0Martin Welschof, CEO BioInvent \u00a0 Financial information Fourth quarter 2020 &#8211; Net sales SEK 98.7 (25.4) million. &#8211; Profit\/loss after tax SEK 28.5 \u00a0(-40.9) million. &#8211; Profit\/loss after tax per share before and after dilution SEK 0.74\u00a0 (-2.04). &#8211; &hellip; Continue reading &quot;BioInvent International Financial Statement January 1 &#8211; December 31, 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-23T08:24:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO87845&amp;sd=2021-02-23\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioInvent International Financial Statement January 1 &#8211; December 31, 2020\",\"datePublished\":\"2021-02-23T08:24:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/\"},\"wordCount\":1758,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO87845&amp;sd=2021-02-23\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/\",\"name\":\"BioInvent International Financial Statement January 1 - December 31, 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO87845&amp;sd=2021-02-23\",\"datePublished\":\"2021-02-23T08:24:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO87845&amp;sd=2021-02-23\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO87845&amp;sd=2021-02-23\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioinvent-international-financial-statement-january-1-december-31-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioInvent International Financial Statement January 1 &#8211; December 31, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioInvent International Financial Statement January 1 - December 31, 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/","og_locale":"en_US","og_type":"article","og_title":"BioInvent International Financial Statement January 1 - December 31, 2020 - Market Newsdesk","og_description":"Promising early interim efficacy data on our lead drug candidate PR Newswire LUND, Sweden, Feb. 23, 2021 \/PRNewswire\/ &#8212; &#8220;BioInvent has started 2021 with significant positive momentum We reported promising interim efficacy data from the ongoing Phase I\/IIa trial of our lead drug candidate BI-1206.The company also closed a successful SEK 962 million financing round, expanding our institutional shareholder base. Furthermore, we announced the expansion of our clinical pipeline to include two further drug candidates for the treatment of solid tumors.&#8221; &#8211;\u00a0Martin Welschof, CEO BioInvent \u00a0 Financial information Fourth quarter 2020 &#8211; Net sales SEK 98.7 (25.4) million. &#8211; Profit\/loss after tax SEK 28.5 \u00a0(-40.9) million. &#8211; Profit\/loss after tax per share before and after dilution SEK 0.74\u00a0 (-2.04). &#8211; &hellip; Continue reading \"BioInvent International Financial Statement January 1 &#8211; December 31, 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-23T08:24:38+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO87845&amp;sd=2021-02-23","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioInvent International Financial Statement January 1 &#8211; December 31, 2020","datePublished":"2021-02-23T08:24:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/"},"wordCount":1758,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO87845&amp;sd=2021-02-23","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/","name":"BioInvent International Financial Statement January 1 - December 31, 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO87845&amp;sd=2021-02-23","datePublished":"2021-02-23T08:24:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO87845&amp;sd=2021-02-23","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO87845&amp;sd=2021-02-23"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioinvent-international-financial-statement-january-1-december-31-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioInvent International Financial Statement January 1 &#8211; December 31, 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441440","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=441440"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/441440\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=441440"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=441440"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=441440"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}